Navigation Links
QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
Date:5/21/2008

life. These results from the Phase 3 clinical trial for Ophena(TM) show that a non-estrogen therapy may provide significant benefits for post-menopausal women affected by vaginal dryness and dyspareunia, two of the most common and debilitating symptoms of vulvovaginal atrophy," said James A. Simon, M.D., CCD, FACOG, Clinical Professor of Obstetrics and Gynecology at the George Washington University.

Ophena(TM) is a novel selective estrogen receptor modulator (SERM) that is being studied as a non-estrogen alternative for the treatment of postmenopausal vaginal syndrome (PVS), also known as vaginal atrophy. The only FDA approved products currently available to treat PVS contain the hormone estrogen. Treatment with estrogen replacement therapy has been associated with certain health risks including an increased risk of breast cancer.

"For women who are concerned about the health risks of estrogen therapy, currently available treatment options for symptoms of vulvovaginal atrophy are limited and inadequate. These study results indicate that Ophena(TM) has the potential to be the first non-estrogen treatment option that provides a clear clinical benefit. We are working to advance the development program for Ophena(TM) to make this important therapy available to all women who would benefit from it," said Robert Zerbe, M.D., president and chief executive officer of QuatRx.

About Postmenopausal Vaginal Syndrome

Postmenopausal vaginal syndrome (PVS) is a chronic and progressive condition characterized by symptoms including vaginal dryness, sexual pain (dyspareunia), and irritation. Declining estrogen levels during menopause can cause tissues of the vaginal lining to grow thinner and to lose elasticity, a condition known as atrophy. Dryness and irritation associated with reductions in vaginal secretions often cause pain or bleeding during sexual intercourse. The decline in estrogen also contributes to an increase in vaginal pH, creating an environ
'/>"/>

SOURCE QuatRx Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine technology :

1. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... NEW YORK , May 17, 2013 /PRNewswire-iReach/ -- ... for Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life ... offering free PALS, BLS and ACLS online ... free manuals, people simply need to build an account ... review materials for these programs, United Medical Education is ...
(Date:5/17/2013)... , May 17, 2013  Serving a region of 650,000 ... , Caribbean Imaging and Radiation Therapy (CIRT, ... capabilities with the acquisition of an Elekta Versa HD™ system, ... HD offers clinicians the versatility to deliver conventional therapies to ... also enabling treatment of highly complex cancers that require extreme ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
Breaking Medicine Technology:ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2Puerto Rico's Caribbean Imaging and Radiation Therapy Center Orders Elekta's New Versa HD System for Treatment of Cancer Patients 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... Data also showed differences in gastrointestinal and lipid ... among study population, PRINCETON, N.J., Feb. 6 ... announced results from the CASTLE study, in which,300 ... 100 mg of,ritonavir (REYATAZ/r) showed similar antiviral efficacy ...
... is,a life saving treatment option for people with ... far exceeds the supply. Each year,only about one-third ... receive one, and,some patients die while waiting. In ... how the current system for allocating donor,organs in ...
Cached Medicine Technology:CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 2Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System 3
(Date:5/18/2013)... May 18, 2013 The Ayurvedic practitioner ... education institution in the West. Program is available in ... Ayurveda is a healing modality practiced for over 5,000 ... is considered that health begins when an individual lives ... of their individual needs. Ayurveda aims to heal an ...
(Date:5/18/2013)... Meadows, IL (PRWEB) May 18, 2013 ... urges Oregon Gov. John A. Kitzhaber, M.D., (D) to ... state law by prohibiting minors under the age of ... Oregon would become the third state in the nation ... already have enacted similar indoor tanning bans for minors. ...
(Date:5/18/2013)... 18, 2013 Spectrum Surgical Instruments ... May 17-22 in Austin, TX where thousands of ... and networking opportunities. , Spectrum Surgical/STERIS will ... scope repair capabilities and certified pre-owned equipment. ... information on proper instrument care of flexible endoscopes. ...
(Date:5/18/2013)... 2013 John Ravera, D.D.S., a Newport ... a new member to his dental team, Courtney Marino. , ... field for over 10 years. She received her degree from ... elected a member of Sigma Pi Alpha, a national honor ... working with patients of all ages, helping them understand the ...
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 ... latest update to consumers about transvaginal mesh ... federal court Resource4thePeople reports that plaintiffs have ... to court documents. , The rulings came ... District Court in the Southern District of ...
Breaking Medicine News(10 mins):Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 2Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 3Health News:2013 Alleged Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Defendants Ordered to Provide Testimony, Documents 4
... as a second-line therapy had a significantly improved ... treated with topotecan (Hycamtin), according to research presented ... in Amsterdam, hosted by the International Association for ... showed significant improvements in tumor shrinkage, symptom control ...
... School of Public Health (HSPH), Massachusetts Institute of Technology ... Providence Health & Services have found that expanding low ... use, reduces financial strain on covered individuals, and improves ... study to evaluate the impact of insuring the uninsured ...
... teaches children about fitness and encourages them to live ... has statistical evidence that sports participation is also beneficial ... Keren Shahar, a Ph.D. student at Tel Aviv University,s ... supervision of Prof. Tammie Ronen and Prof. Michael Rosenbaum, ...
... WEDNESDAY, July 6 (HealthDay News) -- Move over, Lyme disease: ... of the country, and this one can kill. Known ... that attacks blood cells, causing flu-like symptoms that can make ... caused by bacteria, babesia microti parasites are carried by deer ...
... , WEDNESDAY, July 6 (HealthDay News) -- The next time you ... this: The high you get from eating all that fat may ... marijuana. The same mechanism that gives pot smokers the ... -- appears to help explain why people like fat so much, ...
... Amsterdam - 6 July, 2011 - Elsevier, a ... products and services, today announced the availability of ... SciVal Experts. The tool seamlessly links opportunities within ... profiles within SciVal Experts, automating the process of ...
Cached Medicine News:Health News:Medicaid increases use of health care, decreases financial strain, improves health 2Health News:Medicaid increases use of health care, decreases financial strain, improves health 3Health News:Leaving anger on the field 2Health News:A Deadly New Reason to Avoid Deer Ticks 2Health News:A Deadly New Reason to Avoid Deer Ticks 3Health News:Binge Eating May Be a High All Its Own 2Health News:Binge Eating May Be a High All Its Own 3Health News:Elsevier matches funding opportunities to researcher expertise 2
... basic principle of a competitive enzyme immunoassay ... antigen and an labelled antigen bound to ... antiserum . The amount of enzyme conjugate ... antibody is inversely proportional to the concentration ...
... Progesterone (pregn-4-ene-3, 20-dione) is a C21 ... a double bond between C-4 and C-5 ... hormone which, in conjunction with estrogens, regulates,the ... it is particularly important in preparing the,endometrium ...
Microalbumin Turbidimetric Lipid / Protein Quantification 021-SDX001...
... known as Kininase II, is a dipeptidyl ... of at least 129,000. The structure of ... a polysaccharide residue and a zinc atom. ... types such as neuronal cells and renal ...
Medicine Products: